Discovery of Oxime Ether Derivatives as Second-Generation PRMT5 Inhibitors for the Treatment of Triple Negative Breast Cancer.
Cheng X, Hu Z, Mao H, Li Z, Wang Z, Tang Y, Huang S, Huang Y, Yin C, Xing H, Chen S, Jiang Y, Hu T, Zuo J, Yan W, Gu H, Wei P, Xu Y, Zhu Q, Zou Y.
Cheng X, et al. Among authors: yin c.
J Med Chem. 2026 Jan 12. doi: 10.1021/acs.jmedchem.5c02570. Online ahead of print.
J Med Chem. 2026.
PMID: 41527338